about
Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tailsCurrent ebola vaccinesArenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategiesEbola haemorrhagic feverEbola virus vaccines: an overview of current approachesEbolavirus is internalized into host cells via macropinocytosis in a viral glycoprotein-dependent mannerA shared structural solution for neutralizing ebolavirusesStructure of an Antibody in Complex with Its Mucin Domain Linear Epitope That Is Protective against Ebola VirusEbola and Marburg virus vaccines.A novel life cycle modeling system for Ebola virus shows a genome length-dependent role of VP24 in virus infectivityThe spatio-temporal distribution dynamics of Ebola virus proteins and RNA in infected cellsVaccines. An Ebola whole-virus vaccine is protective in nonhuman primatesContribution of Sec61α to the life cycle of Ebola virus.Zinc binding activity of human metapneumovirus M2-1 protein is indispensable for viral replication and pathogenesis in vivo.Progress in filovirus vaccine development: evaluating the potential for clinical use.Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever virusesRole of Ebola virus VP30 in transcription reinitiation.DNA topoisomerase 1 facilitates the transcription and replication of the Ebola virus genome.Replication-deficient ebolavirus as a vaccine candidate.Phosphorylation of Human Metapneumovirus M2-1 Protein Upregulates Viral Replication and Pathogenesis.Reverse genetics systems as tools for the development of novel therapies against filoviruses.Chasing Ebola through the Endosomal Labyrinth.Ebola vaccines in clinical trial: The promising candidates.Ebola virus vaccines - reality or fiction?Ebola virus infection modeling and identifiability problems.The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.Creation of a completely helper cell-dependent recombinant morbillivirus.Bluetongue virus VP6 acts early in the replication cycle and can form the basis of chimeric virus formationForty Years of Ebolavirus Molecular Biology: Understanding a Novel Disease Agent Through the Development and Application of New Technologies.Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses.Mapping Phylogenetic Trees to Reveal Distinct Patterns of Evolution.Generation of vero cells expressing ebola virus glycoprotein.Electron Microscopy of Ebola Virus-Infected Cells.Ebola Virus Stability Under Hospital and Environmental Conditions.Knockdown of Ebola virus VP24 impairs viral nucleocapsid assembly and prevents virus replication.A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entryEbola virus proteins NP, VP35, and VP24 are essential and sufficient to mediate nucleocapsid transport.Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola VirusSystematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
P2860
Q21134356-D887F97D-0229-4A89-A3B9-CF850C79062FQ21534720-91CC204C-EEDD-41B1-92B5-7477F1029CB6Q24599295-E21E6DBB-2FC3-4540-A388-6B93FF02BD64Q24629338-02A7282B-2B4F-44AB-B337-B068A32974D4Q26999232-71806BD6-C6D4-4EC8-B25F-9E92FC63541EQ27313378-17509691-3415-46A1-BFDC-4C491004BEBFQ27675675-15B7F555-9BC0-412C-833D-6F4B004923E0Q27676230-FB97D1F7-C370-4BF9-B596-69EA924C7071Q30234637-40519652-56DF-4866-845F-FEB2F0DD2FC3Q34262347-D44F009E-9B35-4824-811E-507A4C62A782Q34326340-8A675DF4-2E46-418C-BAA8-A1EAED3B7ADEQ34468847-3B93C58F-AC6C-4950-A051-719D399F2B62Q35299870-0BD1AC4E-C314-47EE-8B59-090C59990A05Q35760424-F173F92C-DE0B-47C5-A93C-B3EADF0A5620Q36100545-F195EEDD-C804-4CA5-A984-BAE184742A4AQ36650409-2B2EF255-4D35-4B75-8209-B6766DE059BCQ36994598-FCA08262-78A0-4EBA-91D7-E1564D17AFECQ37123264-A0B13EA3-F7C0-4594-A02C-8BEF76CD05C1Q37145203-4B7CF086-7523-41F2-847B-2D82058CECF7Q37174437-AC6F5C8A-AAF9-432F-93C2-893BA9622C5DQ38244444-16AA0807-C894-43A3-86D3-E5CB40B7E6D4Q38560342-A55A01AA-DF37-4D27-BC7A-5DEEF2225017Q38808678-7A57A5D9-FCAB-4F1B-9838-F3B5410CAEA6Q38881265-D35754A9-0F4F-45BD-9FE2-1363DC780976Q39013896-7F7A07AD-3DDB-4413-AF79-204C31C705ECQ39083915-CDAB85C4-C934-412A-9A6D-804A4F882939Q39191416-62986D1A-3001-4C6B-AF04-EE7D78F90786Q39225711-E0CCFBF1-9D98-4A67-9352-C897297F9558Q39345592-80B0B6D1-4CCC-411B-BEB0-C11997A8B29AQ39625153-82DE15B7-8DC2-4A7B-AFF2-40C0D22C4D46Q39655890-B057882A-C9A3-4768-9AE1-C5B3FA34F63DQ39855764-06B0439C-776D-4261-8804-377C39E880BFQ40054430-7C8AAA9E-8E7B-44DA-A28E-698983CA2E07Q40102162-35C545B1-77B3-4546-8661-24A1CD57961CQ40309150-9C1EB748-58BD-4372-A5E8-93FF2C6562BCQ40376100-10A26DB1-61EF-4286-AD55-25F509A7F094Q47552823-76ACCD58-4D58-4AF5-BC95-3A569D3EC7DDQ56535662-0E6110D9-8B36-4610-9577-C6372D2EFBE6Q56558172-BE3212F2-684A-4C67-BE02-1E41B5F97312
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Generation of biologically contained Ebola viruses.
@ast
Generation of biologically contained Ebola viruses.
@en
type
label
Generation of biologically contained Ebola viruses.
@ast
Generation of biologically contained Ebola viruses.
@en
prefLabel
Generation of biologically contained Ebola viruses.
@ast
Generation of biologically contained Ebola viruses.
@en
P2093
P2860
P50
P356
P1476
Generation of biologically contained Ebola viruses.
@en
P2093
Gabriele Neumann
Jin Hyun Kim
Peter Halfmann
Takeshi Noda
P2860
P304
P356
10.1073/PNAS.0708057105
P407
P577
2008-01-22T00:00:00Z